I-Scan a Novel Endoscopic Tool for the Macroscopic Identification of Mucosal Lesions
NCT ID: NCT03298776
Last Updated: 2019-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
758 participants
INTERVENTIONAL
2013-09-26
2019-01-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Endoscopy provides an advantage over other noninvasive or minimally invasive procedures in that it allows both direct visualisation of the mucosa but direct and accurate sampling of abnormalities for histological examination. However standard endoscopy does have some limitations particularly with small lesions and pan mucosal changes. Some lesions may be entirely benign and require no further intervention but as a result of difficulty with accurate endoscopic characterization of lesions in many cases unnecessary biopsies or polypectomies are undertaken. Therefore any technology that can augment the use of standard endoscopy to minimise unnecessary intervention should be encouraged. IScan is a digital enhancement technique available with Pentax endoscopes. There have been other novel endoscopic advances for example, Narrow band imaging but these have not been adopted widely for a number of reasons including technical difficulties or patient tolerability. The aim of this study is to assess whether Pentax IScan technology is a reliable method of improving our recognition of macroscopic mucosal lesions compared to standard white light endoscopy
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Usefulness of I-scan in Screening Colonoscopy
NCT01417611
I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia
NCT02516735
Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy
NCT00792649
Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma
NCT01642797
Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps
NCT01133041
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following recruitment patients will be randomly allocated to receive standard white light endoscopy or standard white light endoscopy plus I-Scan using a random number generator at www.random.org with possible values of 0 or 1. Those with a 0 will receive standard endoscopy and those with a 1 will receive standard endoscopy plus I-Scan. Both arms will undergo standard endoscopic evaluation including appropriate biopsies by fully trained experienced endoscopists with Joint Advisory Group (JAG) accreditation for endoscopy. The investigators will be initially blinded to the indication for endoscopy until the I-Scan has been utilised at which point the indication will be revealed to ensure patient safety. Patients will have biopsies only by the clinical indication. No extra biopsies that would not normally be clinically justified will be taken. Following the procedure all patients will be asked to evaluate the tolerability of their test using a validated 10 point likert scale. All procedures will be recorded on an anonymised basis using a unique research identifier and subsequently reviewed by other expert endoscopists within the department to allow us to accurately assess the reliability and interobserver variability of the test. Each of the endoscopists will be fully trained in standard endoscopy and will be blinded to the indication for the procedure.
The study will be a randomised controlled trial. Given the nature of the study it is not possible to blind the investigators to the procedure type. The investigator carrying out the procedure will however be blinded to the indication for the procedure until the I-Scan has been used as this could lead to bias. The endoscopists reviewing the images will be blinded to all patient information and indications for the endoscopy throughout the study period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
standard white light endoscopy
Patients will undergo the standard of care which is standard white light endoscopy
Standard endoscopy
Patients referred for standard endoscopy to receive standard of care only
Endoscopy and I-Scan
Patients will undergo standard of care endoscopy plus the I-Scan
I-Scan
I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
I-Scan
I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
Standard endoscopy
Patients referred for standard endoscopy to receive standard of care only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with a known endoscopic diagnosis
* Patients with abnormal coagulation or any other contraindication to use of standard biopsy or polypectomy techniques used in routine diagnostic endoscopic procedures
* Patients who are unable to understand English or give informed consent
* Patients under the age of 16
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheffield Teaching Hospitals NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Sanders
Role: PRINCIPAL_INVESTIGATOR
Sheffield Teaching Hospitals NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STH18011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.